1
|
Dallolio L, Gallè F, Masini A, Valeriani F, Ceciliani A, di Cagno A, Galeone D, Pecoraro P, Valerio G, Liguori G, Romano Spica V, Brandi G, Baldelli G, Capelli G, Coco D, Corradi M, Cortis E, Deiana P, Di Rosa E, Marini S, Mulato R, Parisi A, Pesce C, Riegger S, Staiano A, Siniscalco A, Trombetta M, Ubaldi F. Active breaks: a strategy to counteract sedentary behaviors for Health Promoting Schools. A discussion on their implementation in Italy. Ann Ig 2023; 35:202-212. [PMID: 35788249 DOI: 10.7416/ai.2022.2532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Abstract School Active Breaks are short bouts of physical activity (5-15 minutes) conducted by appropriately trained teachers and delivered during or between curricular lessons. They are a good strategy to counteract sedentary behaviors, and a growing body of evidence shows that they can represent also a tool to promote and improve health, school wellbeing and academic achievements. On 19 February 2022, the Working Group on Movement Sciences for Health of the Italian Society of Hygiene, Preventive Medicine and Public Health organized an Awareness Day on the effectiveness, usefulness and feasibility of School Active Breaks, opened to teachers, educators, school leaders, pediatricians, personnel from Departments of Prevention and Public Health and Health Policy-makers. During the event, the testimonies about the experiences already carried out in Italy showed that School Active Breaks are an effective intervention that each school can easily include in its educational offer and apply in any context.
Collapse
Affiliation(s)
- L Dallolio
- Department of Biomedical and Neuromotor Science, University of Bologna, Bologna, Italy
| | - F Gallè
- Department of Movement Sciences and Wellbeing, University of Naples "Parthenope", Italy
| | - A Masini
- Department of Biomedical and Neuromotor Science, University of Bologna, Bologna, Italy
| | - F Valeriani
- Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Rome, Italy
| | - A Ceciliani
- Department for Life Quality Studies, University of Bologna, Bologna, Italy
| | - A di Cagno
- Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Rome, Italy
| | - D Galeone
- General Directorate for Health Prevention, Ministry of Health, Rome, Italy
| | - P Pecoraro
- Local Health Agency Naples 3 South, Naples, Italy
| | - G Valerio
- Department of Movement Sciences and Wellbeing, University of Naples "Parthenope", Italy
| | - G Liguori
- Department of Movement Sciences and Wellbeing, University of Naples "Parthenope", Italy
| | - V Romano Spica
- Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Rome, Italy
| | - G Brandi
- Department of Biomolecular Sciences, Public Health Unit, University "Carlo Bo", Urbino, Italy
| | - G Baldelli
- School Active Breaks awareness day, Italy.,Department of Biomolecular Sciences, Public Health Unit, University "Carlo Bo", Urbino, Italy
| | - G Capelli
- School Active Breaks awareness day, Italy.,National Centre for Diseases Prevention and Health Promotion, National Institutes of Health, Rome, Italy
| | - D Coco
- School Active Breaks awareness day, Italy.,Department of Education, University of Rome "Roma Tre", Rome, Italy
| | - M Corradi
- School Active Breaks awareness day, Italy.,Department of Life, Health and Environmental Sciences, University of L'Aquila, Italy
| | - E Cortis
- School Active Breaks awareness day, Italy.,Pediatric Unit, Sant'Eugenio Hospital, ASL Rome 2, Rome, Italy
| | - P Deiana
- School Active Breaks awareness day, Italy.,Office of School Sport Policies, Italian Ministry of Education, Rome, Italy
| | - E Di Rosa
- School Active Breaks awareness day, Italy.,Office of School Sport Policies, Italian Ministry of Education, Rome, Italy
| | - S Marini
- Department for Life Quality Studies, University of Bologna, Bologna, Italy.,School Active Breaks awareness day, Italy
| | - R Mulato
- School Active Breaks awareness day, Italy.,Moving School 21 ONLUS, Bologna, Italy
| | - A Parisi
- Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Rome, Italy.,School Active Breaks awareness day, Italy
| | - C Pesce
- School Active Breaks awareness day, Italy.,Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Rome, Italy
| | - S Riegger
- School Active Breaks awareness day, Italy.,Moving School 21 ONLUS, Bologna, Italy
| | - A Staiano
- School Active Breaks awareness day, Italy.,Department of Translational Science, University of Naples, Federico II, Naples, and Italian Society of Pediatrics (SIP), Italy
| | - A Siniscalco
- School Active Breaks awareness day, Italy.,Dinamica Tai Chi Chuan e Arti associate A.S.D., Rome, Italy
| | - M Trombetta
- School Active Breaks awareness day, Italy.,"FairPlay4U" Educational Project for School, Galatea Communications, Rome, Italy
| | - F Ubaldi
- Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Rome, Italy.,School Active Breaks awareness day, Italy
| |
Collapse
|
2
|
Amagliani G, Baldelli G, Italiano P, Frisina P, Schiavano GF, Brandi G, De Santi M. Effect of COVID-19 isolation measures on physical activity of children and their parents, and role of the family environment: a cross-sectional study. Ann Ig 2023; 35:159-177. [PMID: 35762445 DOI: 10.7416/ai.2022.2535] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Background The rigorous isolation measures due to the COVID-19 pandemic seriously impacted children's lifestyles. A descriptive cross-sectional study was carried out to collect and analyze information about physical activity habits of children and their parents during the social distancing period resulting from the COVID-19 pandemic. Methods An online questionnaire was administered to 363 families (507 children aged 5-13) recruited by convenience sampling, asking for physical activity type and frequency before, during, and after the lockdown period (9th March - May 3rd 2020), education, outdoor spaces, and children's weight gain perception. Results Results show a remarkable decrease in children's physical activity during lockdown (88.9 vs 39.8% active children) associated with older age and low availability of outdoor spaces (p<0.001). Parents' physical activity was related to educational level, and a slight but significant correlation between parents' education and children's physical activity was found, especially with father's university degree (p<0.05). Active mothers significantly influenced children's physical activity during the lockdown, especially if not engaged in smart working. The return to an active lifestyle by children did not reach previous levels (75.9% active children) and was directly related to parent's physical activity. Finally, the risk of weight gain was lower in active children during the lockdown (OR = 0.46; p<0.001). Conclusions This work highlights the importance of physical activity during a pandemic event to prevent the risk of gaining weight, and underlines the relevance of the entire family system as a source of promotion of healthy behaviors in children.
Collapse
Affiliation(s)
- G Amagliani
- Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino (PU), Italy
| | - G Baldelli
- Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino (PU), Italy
| | - P Italiano
- Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino (PU), Italy
| | - P Frisina
- Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino (PU), Italy
| | - G F Schiavano
- Department of Humanities, University of Urbino"Carlo Bo", Urbino (PU), Italy
| | - G Brandi
- Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino (PU), Italy
| | - M De Santi
- Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino (PU), Italy
| |
Collapse
|
3
|
Amatori S, Sisti D, Perroni F, Brandi G, Rocchi MBL, Gobbi E. Physical activity, sedentary behaviour and screen time among youths with Down syndrome during the COVID-19 pandemic. J Intellect Disabil Res 2022; 66:903-912. [PMID: 35445779 PMCID: PMC9115083 DOI: 10.1111/jir.12933] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 03/17/2022] [Accepted: 04/06/2022] [Indexed: 06/14/2023]
Abstract
BACKGROUND The COVID-19-related restrictions hampered habitual physical activity (PA), particularly affecting the more vulnerable, such as people with Down syndrome (DS). The study aimed to investigate changes in PA, sedentary behaviour (SB) and screen time (ST) of youths with DS, before, during and after the restrictions, also in relation to parental PA levels. METHODS A cross-sectional design with a retrospective assessment of variables for the before and during restrictions periods was adopted. Parents of youths with DS completed an online questionnaire. Sociodemographic aspects, weekly PA levels and youths' daily SB and ST were investigated, referring to three time-points: before the pandemic, during the restrictions and the restrictions-easing phase. RESULTS A total of 57 parents voluntarily participated in the study, proxy-reporting on their child (male = 41, female = 16, age = 21.4 ± 7.7 years). A repeated measures multivariate analysis of variance showed negative effects of restrictions (P < 0.05) on PA levels, SB and ST, independently from sociodemographic characteristics. In the restrictions-easing phase, PA levels did not return to before the pandemic values (P < 0.05). A positive correlation between parents and their child's PA was detected before the pandemic (r = 0.38; P < 0.01), no longer reported in the restrictions-easing phase. CONCLUSIONS The findings showed the negative impact of restrictions on youths with DS lifestyle. Moreover, the importance of addressing the needs of the disabled community including the whole family is highlighted.
Collapse
Affiliation(s)
- S. Amatori
- Department of Biomolecular SciencesUniversity of Urbino Carlo BoUrbinoItaly
| | - D. Sisti
- Department of Biomolecular SciencesUniversity of Urbino Carlo BoUrbinoItaly
| | - F. Perroni
- Department of Biomolecular SciencesUniversity of Urbino Carlo BoUrbinoItaly
| | - G. Brandi
- Department of Biomolecular SciencesUniversity of Urbino Carlo BoUrbinoItaly
| | - M. B. L. Rocchi
- Department of Biomolecular SciencesUniversity of Urbino Carlo BoUrbinoItaly
| | - E. Gobbi
- Department of Biomolecular SciencesUniversity of Urbino Carlo BoUrbinoItaly
| |
Collapse
|
4
|
Bocconcelli M, Natalucci V, Ferri Marini C, Annibalini G, Sisti D, Lucertini F, Vallorani L, De Santi M, Rocchi M, Barocci S, Flori M, Brandi G, Catalano V, Villarini A, Barbieri E, Emili R. 181P A randomized controlled trial on the efficacy of supervised exercise training in reducing IGF-1 levels in breast cancer survivors of the Movis’ cohort. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
5
|
Borad M, Javle M, Shaib W, Mody K, Bergamo F, Harris W, Damjanov N, Macarulla T, Brandi G, Masi G, Droz Dit Busset M, Boncompagni A, Dimova-Dobreva M, Engelhardt M, Saulay M, Halfdanarson T, Knox J, Abou-Alfa G, Personeni N, Mazzaferro V. 59P Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
6
|
Tober N, Filippini D, Pagani R, Forti L, Burrafato G, Brandi G, Gennari A. P-144 Quality of life assessment in biliary tract cancer: A systematic review of phase 2 and 3 clinical trials published between 2010 and 2021. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
7
|
Rizzo A, Ricci AD, Brandi G. Bile cell‑free DNA: a game changer for management of biliary tract cancer? ESMO Open 2022; 7:100389. [PMID: 35121524 PMCID: PMC8818922 DOI: 10.1016/j.esmoop.2022.100389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2021] [Revised: 12/07/2021] [Accepted: 12/12/2021] [Indexed: 11/18/2022] Open
Affiliation(s)
- A Rizzo
- Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
| | - A D Ricci
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - G Brandi
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| |
Collapse
|
8
|
Bögli SY, Utebay D, Smits N, Westphal LP, Hirsbrunner L, Unseld S, Keller E, Brandi G. Sex-related differences of invasive therapy in patients with aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien) 2022; 164:2899-2908. [PMID: 35986220 PMCID: PMC9613555 DOI: 10.1007/s00701-022-05345-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Accepted: 08/11/2022] [Indexed: 02/01/2023]
Abstract
BACKGROUND Sex-related differences in patients with aneurysmal subarachnoid hemorrhage (aSAH) exist. More females than males are affected. Aneurysm location is associated to sex. The relationship between sex and outcome, however, is unclear. Possible differences in management might influence the occurrence of primary and secondary brain injury and thus outcome. The study compares demographics, intensity of treatment, complications, and outcome among females and males with aSAH. METHODS All consecutive patients with aSAH admitted to the neurocritical care unit, University Hospital Zurich over a 5-year period were eligible in this retrospective study. Patients' characteristics, comorbidities, aSAH severity, frequency of vasospasm/delayed cerebral ischemia, frequency of invasive interventions, and 3-month outcome were compared by sex. Univariate analysis was performed with the data dichotomized by sex, and outcome. Multivariate analysis for prediction of outcomes was performed. RESULTS Three hundred forty-eight patients were enrolled (64% females). Women were older than men. Comorbidities, scores at admission, and treatment modality were comparable among males and females. Vasospasm and DCI occurred similarly among females and males. Interventions and frequency of intraarterial spasmolysis were comparable between sexes. In the multivariate analysis, increasing age, female sex, increasing comorbidities, WFNS and Fisher grade, and presence of delayed cerebral ischemia were predictors of unfavorable outcome when considering all patients. However, after excluding death as a possible outcome, sex did not remain a predictor of unfavorable outcome. CONCLUSIONS In the study population, women with aSAH might have present a worse outcome at 3 months. However, no differences by sex that might explain this difference were found in intensity of treatment and management.
Collapse
Affiliation(s)
- S. Y. Bögli
- grid.412004.30000 0004 0478 9977Institute for Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland ,grid.412004.30000 0004 0478 9977Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - D. Utebay
- grid.412004.30000 0004 0478 9977Institute for Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
| | - N. Smits
- grid.412004.30000 0004 0478 9977Institute for Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
| | - L. P. Westphal
- grid.412004.30000 0004 0478 9977Institute for Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
| | - L. Hirsbrunner
- grid.412004.30000 0004 0478 9977Institute for Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
| | - S. Unseld
- grid.412004.30000 0004 0478 9977Institute for Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
| | - E. Keller
- grid.412004.30000 0004 0478 9977Institute for Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland ,grid.7400.30000 0004 1937 0650Department of Neurosurgery and Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland
| | - G. Brandi
- grid.412004.30000 0004 0478 9977Institute for Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
9
|
Frega G, Kepp O, Turchetti D, Rizzo A, Pantaleo MA, Brandi G. Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms. Transl Oncol 2021; 14:101224. [PMID: 34592590 PMCID: PMC8482038 DOI: 10.1016/j.tranon.2021.101224] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 08/31/2021] [Accepted: 09/10/2021] [Indexed: 11/30/2022] Open
Abstract
The genetic background and the antigenic landscape of cancer cells play a critical role in the response to immunotherapies. A high tumor antigenicity, together with an increased adjuvanticity potentially induced by a peculiar type of cell death, namely immunogenic cell death (ICD), could foster the response to immunogenic therapies. The gestational trophoblastic neoplasm (GTN) is a one-of-a-kind cancer in the oncological landscape due to its exclusive genomic makeup. The prognosis of GTN is significantly better than non-gestational trophoblastic neoplasm (nGTN). Due to its peculiar genetic inheritance, GTN potentially constitutes a singular archetype in the immuno-oncological field.
Collapse
Affiliation(s)
- G Frega
- Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni n.15, 40138 Bologna, Italy.
| | - O Kepp
- Equipe labellisée par la Ligue contre le cancer, INSERM UMR1138, Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France
| | - D Turchetti
- Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; U.O. Genetica Medica, Policlinico S. Orsola-Malpighi, Centro di Ricerca sui Tumori Ereditari, Bologna Italy
| | - A Rizzo
- Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni n.15, 40138 Bologna, Italy
| | - M A Pantaleo
- Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni n.15, 40138 Bologna, Italy
| | - G Brandi
- Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni n.15, 40138 Bologna, Italy
| |
Collapse
|
10
|
Bisello S, Bertini F, Tolento G, Renzulli M, Medici F, Benini A, Vallerossa D, Macchia G, Deodato F, Cilla S, Cellini F, Strigari L, Angelini A, Brandi G, Cammelli S, Morganti A, Buwenge M. PO-1236 Stereotactic body radiotherapy in unresectable intrahepatic cholangio-carcinoma: a systematic review. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07687-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
11
|
Rizzo A, Frega G, Palloni A, Piemontese A, Di Federico A, Ricci A, Carloni R, Fabbri F, Novelli M, Tavolari S, Di Marco M, Ravaioli M, Brandi G. P-69 Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
12
|
Tovoli F, Dadduzio V, De Lorenzo S, Garajovà I, Marra F, Trevisani F, Pini S, Granito A, Zagonel V, Brandi G, Piscaglia F. 999P Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
13
|
Emili R, Natalucci V, Marini C, Lucertini F, Vallorani L, Annibalini G, De Santi M, Donati Zeppa S, Agostini D, Gervasi M, Panico A, Sisti D, Rocchi M, Barocci S, Flori M, Brandi G, Stocchi V, Catalano V, Villarini A, Barbieri E. 238P Beneficial effects of exercise in oncology - MoviS: ‘Movement and Health Beyond Care’. Ann Oncol 2020. [PMCID: PMC7506414 DOI: 10.1016/j.annonc.2020.08.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
14
|
Baldelli G, De Santi M, Gervasi M, Annibalini G, Sisti D, Højman P, Sestili P, Stocchi V, Barbieri E, Brandi G. Correction to: The effects of human sera conditioned by high-intensity exercise sessions and training on the tumorigenic potential of cancer cells. Clin Transl Oncol 2020; 23:195. [PMID: 32772345 DOI: 10.1007/s12094-020-02469-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- G Baldelli
- Pharmacology and Public Health Unit, Biomolecular Sciences Department, University of Urbino Carlo Bo, Urbino, PU, Italy
| | - M De Santi
- Pharmacology and Public Health Unit, Biomolecular Sciences Department, University of Urbino Carlo Bo, Urbino, PU, Italy.
| | - M Gervasi
- Exercise and Health Sciences Unit, Biomolecular Sciences Department, University of Urbino Carlo Bo, Urbino, PU, Italy
| | - G Annibalini
- Exercise and Health Sciences Unit, Biomolecular Sciences Department, University of Urbino Carlo Bo, Urbino, PU, Italy
| | - D Sisti
- Service of Biostatistics, Biomolecular Sciences Department, University of Urbino Carlo Bo, Urbino, PU, Italy
| | - P Højman
- Centre of Inflammation and Metabolism (CIM) and Centre for Physical Activity Research (CFAS), Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark
| | - P Sestili
- Exercise and Health Sciences Unit, Biomolecular Sciences Department, University of Urbino Carlo Bo, Urbino, PU, Italy
| | - V Stocchi
- Exercise and Health Sciences Unit, Biomolecular Sciences Department, University of Urbino Carlo Bo, Urbino, PU, Italy
| | - E Barbieri
- Exercise and Health Sciences Unit, Biomolecular Sciences Department, University of Urbino Carlo Bo, Urbino, PU, Italy.,Interuniversity Institute of Myology, Urbino, PU, Italy
| | - G Brandi
- Pharmacology and Public Health Unit, Biomolecular Sciences Department, University of Urbino Carlo Bo, Urbino, PU, Italy
| |
Collapse
|
15
|
De Santi M, Zangara G, Baldelli G, Brandi G. Influence of parental habits and drug use in adolescents' physical activity: a case study of an Italian high school. Ann Ig 2020; 32:541-548. [PMID: 32744585 DOI: 10.7416/ai.2020.2374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Physical activity is considered a fundamental element for health promotion, also during adolescence, contributing to the psycho-physical well-being of the individuals. Here we evaluate the relationship between risk behavior and physical activity habits of adolescents and their parents. METHODS A total of 220 subjects (115 females, 105 males), aged between 14 and 18, were asked about their own and parents' physical activity habits and tobacco, alcohol, and light drug consumption. The chi-square test was used to detect differences between males and females. Categorical principal component analysis and Spearman's correlation were used to find associations between the variables analyzed. RESULTS Our results show a prevalence of an active lifestyle of 52.3%, with no significant gender differences. The consumption of tobacco, alcohol, and light drugs was 28.2, 63.2, and 16.8%, respectively, with a higher prevalence in males and correlated with age. We found a positive correlation between physical activity practice and parents' physical activity, especially between mothers and daughters. Finally, male physical activity practice is inversely related to risk behaviors. CONCLUSIONS Our findings underline the importance of family and parental involvement in promoting health behaviors, such as physical and sports activities, that can represent a powerful educational tool for the prevention of social dangers.
Collapse
Affiliation(s)
- M De Santi
- Department of Biomolecular Sciences, Hygiene Unit, University of Urbino Carlo Bo, Urbino (PU), Italy
| | - G Zangara
- Department of Biomolecular Sciences, Hygiene Unit, University of Urbino Carlo Bo, Urbino (PU), Italy
| | - G Baldelli
- Department of Biomolecular Sciences, Hygiene Unit, University of Urbino Carlo Bo, Urbino (PU), Italy
| | - G Brandi
- Department of Biomolecular Sciences, Hygiene Unit, University of Urbino Carlo Bo, Urbino (PU), Italy
| |
Collapse
|
16
|
Massacesi M, Oliva N, Pucci L, Brandi G, De Santi M. Listeriolysin O antibodies detection in pregnant women: results from an Italian pilot study. Ann Ig 2020; 31:326-332. [PMID: 31268117 DOI: 10.7416/ai.2019.2294] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Listeriosis is a rare infection affecting primarily pregnant women, the elderly and individuals with a weakened immune system and is caused by the ubiquitous bacterium Listeria monocytogenes. Infection during pregnancy can cause severe consequences especially for the fetus, leading to sepsis, premature delivery, stillbirth and miscarriage. STUDY DESIGN A pilot observational study has been conducted in order to establish the prevalence of seroconversion of specific antibodies against a peculiar toxin belonging to L. monocytogenes, listeriolysin O (LLO), in a population of pregnant women from Senigallia (Central Italy) and to find correlations between anti-LLO antibodies seropositivity and health and nutritional information. A total of 60 women were screened for anti-LLO antibody positivity and interviewed during their pregnancies. Statistical analyses were performed to evaluate antibody prevalence in serum samples and potential risk factors. RESULTS The seroprevalence resulted 18% (95% CI, 8.2 - 27.7%), corresponding to 11 pregnant women. Categorical principal component analysis and hierarchical cluster analysis revealed a significant correlation between anti-LLO positivity and gastrointestinal pain events and vomit, fever and diarrhea episodes, and a possible association with consumption of pre-cooked meal. No significant correlation was observed in women with a previous miscarriage or with miscarriage cases in their families. CONCLUSIONS Findings from this pilot study will be used to design a wider study focused on the prevalence of Listeria-specific antibodies in pregnant women and could allow to the identification of nutritional and behavioral habits related to Listeria infection which could lead to significant clinical implications.
Collapse
Affiliation(s)
- M Massacesi
- Principe di Piemonte Hospital, Senigallia (AN), Italy
| | - N Oliva
- Principe di Piemonte Hospital, Senigallia (AN), Italy
| | - L Pucci
- Diatheva SRL, Cartoceto (PU), Italy
| | - G Brandi
- University of Urbino Carlo Bo, Biomolecular Sciences Department, Hygiene Unit, Urbino (PU), Italy
| | - M De Santi
- University of Urbino Carlo Bo, Biomolecular Sciences Department, Hygiene Unit, Urbino (PU), Italy
| |
Collapse
|
17
|
Romano Spica V, Gallè F, Baldelli G, Valeriani F, Di Rosa E, Liguori G, Brandi G. Swimming Pool safety and prevention at the time of Covid-19: a consensus document from GSMS-SItI. Ann Ig 2020; 32:439-448. [PMID: 32578839 DOI: 10.7416/ai.2020.2368] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Public health measures to cope with the Covid-19 pandemic, imposed also a shutdown of sports facilities and swimming pools. Safety issues related to recreational waters were emerging during the lockdown, rising concerns on how and when reopening pools and on how improve their management while SARS-CoV-2 is circulating in the population. The GSMS-SItI, Working Group on Movement Sciences for Health of the Italian Society of Hygiene Preventive Medicine and Public Health, discussed and summarized some indications for a suitable preventive approach. Several measures are highlighted, including social distancing, optimized water management, airflow and microclimatic parameters in the pool as well in the annexed rooms, verification of sanitation procedures. The GSMS-SItI underlines that prevention should be based on monitoring of the local epidemiological situation and on the constant collaboration with the local health authority and the national health service.
Collapse
Affiliation(s)
| | - F Gallè
- University of Napoli "Parthenope", Naples, Italy
| | - G Baldelli
- University of Urbino "Carlo Bo", Urbino, Italy
| | - F Valeriani
- University of Rome "Foro Italico", Rome, Italy
| | | | - G Liguori
- University of Napoli "Parthenope", Naples, Italy
| | - G Brandi
- University of Urbino "Carlo Bo", Urbino, Italy
| | | |
Collapse
|
18
|
Rizzo A, Ricci A, Frega G, Palloni A, Dall'Olio F, Lorenzo SD, Tavolari S, Abbati F, Vasuri F, Di Marco M, Tober N, Nigro M, Mosca M, Mollica V, Maggio I, Tovoli F, Cescon M, Serra C, Ambrosini V, Nanni C, Fanti S, Brandi G. PD-2 Role of pretreatment SUVmax on 18F-FDG PET and clinicopathological features in the prognostic stratification of newly diagnosed intrahepatic cholangiocarcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
19
|
Filippini DM, Grassi E, Palloni A, Carloni R, Casadei R, Ricci C, Serra C, Ercolani G, Brandi G, Di Marco M. Searching for novel multimodal treatments in oligometastatic pancreatic cancer. BMC Cancer 2020; 20:271. [PMID: 32228504 PMCID: PMC7106565 DOI: 10.1186/s12885-020-06718-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Accepted: 03/05/2020] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Metastatic pancreatic cancer has a median overall survival of less than 12 months, even if treated with chemotherapy. Selected patients with oligometastatic disease could benefit from multimodal treatments connecting chemotherapy and surgical treatment or radiofrequency ablation (RFA) of metastases. CASE PRESENTATION We present a patient with oligometastatic pancreatic cancer recurrence who was successfully treated with a multimodal therapeutic approach. A 57-year-old male initially presenting with resectable pancreatic cancer underwent pancreatoduodenectomy. The histopathological diagnosis revealed ductal pancreatic adenocarcinoma with positive surgical resection margins and negative lymph nodes. He completed six cycles of adjuvant therapy with gemcitabine (1000 mg/mq 1,8,15q 28), followed by external radiotherapy (54 Gy in 25 fractions) associated with gemcitabine 50 mg/mq twice weekly. Three years later, the patient developed multiple liver metastases, and he started FOLFIRINOX (oxaliplatin 85 mg/mq, irinotecan 180 mg/mq, leucovorin 400 mg/mq and fluorouracil 400 mg/mq given as a bolus followed by 2400 mg/mq as a 46 h continuous infusion,1q 14) as a first-line treatment. The CT scan showed a partial response after 6 cycles. After multidisciplinary discussion, the patient underwent a laparotomic metastasectomy of the three hepatic lesions. After additional postsurgical chemotherapy with 4 cycles of the FOLFIRINOX schedule, the patient remained free of recurrence for 12 months. A CT scan showed a new single liver metastasis, which was treated with radiofrequency ablation (RFA). A second radiofrequency ablation was performed when the patient developed another single liver lesion 12 months after the first RFA; currently, the patient is free from recurrence with an overall survival of 6 years from the diagnosis. CONCLUSIONS Our case has benefited from successful multimodal treatment, including surgical and local ablative techniques and systemic chemotherapy. A multimodal approach may be warranted in selected patients with oligometastatic pancreatic cancer and could improve overall survival. Further research is needed to investigate this approach.
Collapse
Affiliation(s)
- D M Filippini
- Department of Experimental, Diagnostic and Specialty Medicine University of Bologna, Sant'Orsola-Malpighi Hospital, Massarenti Street 11, 40100, Bologna, Italy
| | - E Grassi
- Department of Experimental, Diagnostic and Specialty Medicine University of Bologna, Sant'Orsola-Malpighi Hospital, Massarenti Street 11, 40100, Bologna, Italy.
| | - A Palloni
- Department of Experimental, Diagnostic and Specialty Medicine University of Bologna, Sant'Orsola-Malpighi Hospital, Massarenti Street 11, 40100, Bologna, Italy
| | - R Carloni
- Department of Experimental, Diagnostic and Specialty Medicine University of Bologna, Sant'Orsola-Malpighi Hospital, Massarenti Street 11, 40100, Bologna, Italy
| | - R Casadei
- Department of Medical and Surgical Sciences, University of Bologna, Sant'Orsola-Malpighi Hospital, Bologna, Italy
| | - C Ricci
- Department of Medical and Surgical Sciences, University of Bologna, Sant'Orsola-Malpighi Hospital, Bologna, Italy
| | - C Serra
- Department of Organ Failure and Transplantation, Ultrasound Unit, Sant'Orsola-Malpighi Hospital, Bologna, Italy
| | - G Ercolani
- Department of Medical and Surgical Sciences, University of Bologna, Sant'Orsola-Malpighi Hospital, Bologna, Italy.,General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, Italy
| | - G Brandi
- Department of Experimental, Diagnostic and Specialty Medicine University of Bologna, Sant'Orsola-Malpighi Hospital, Massarenti Street 11, 40100, Bologna, Italy
| | - M Di Marco
- Department of Experimental, Diagnostic and Specialty Medicine University of Bologna, Sant'Orsola-Malpighi Hospital, Massarenti Street 11, 40100, Bologna, Italy
| |
Collapse
|
20
|
Viza D, Pizza G, De Vinci C, Brandi G, Ablashi D. Transfer Factor as an Option for Managing the COVID-19 Pandemic. Folia Biol (Praha) 2020; 66:86-90. [PMID: 33069187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Covid-19 or SARS-CoV-2, a new RNA virus with high infectivity, and seemingly low mutability, which appeared in 2019 in the Wuhan province of China, has created a pandemic with dire consequences. At the end of May 2020, it became the first cause of mortality. As no treatment or vaccine may become available before many months, and because occurrence of similar pandemics is only a matter of time, arguments are presented here for testing the effect of transfer factor (TF), an immunomodulator devoid of toxicity, which has been extensively studied in the past for the treatment and prevention of viral infections.
Collapse
Affiliation(s)
- D Viza
- Immunobiology Laboratory, Faculté de Médicine, Paris 6, France
| | - G Pizza
- Immunotherapy dept., S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - C De Vinci
- Immunotherapy dept., S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - G Brandi
- Medical Oncology, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - D Ablashi
- HHV-6 Foundation, Santa Barbara, CA, USA
| |
Collapse
|
21
|
Frega G, Tavolari S, Indio V, Deserti M, Tarantino G, Palloni A, De Lorenzo S, Rizzo A, Astolfi A, Brandi G. Potentially actionable mutations in intrahepatic cholangiocarcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz413.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
De Santi M, Baldelli G, Brandi G. Use of hormones in doping and cancer risk. Ann Ig 2019; 31:590-594. [PMID: 31616903 DOI: 10.7416/ai.2019.2319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Hormones with anabolic properties such as growth hormone (GH) and insulin-like growth factor-1 (IGF-1) are commonly abused among professional and recreational athletes to enhance physical ability. Despite their adverse effects are well-documented, the use of GH and IGF-1 has recently grown. This article highlights the anabolic activity related to mechanisms of cancer development and progression. GH/IGF-1 axis is able to activate cellular mechanisms that modulate every key stage of cancer formation and progression, such as inhibition of apoptosis, resistance to treatments, and induction of angiogenesis, metastatic process and cell proliferation. Results from pre-clinical studies and epidemiological observations in patients with an excess of GH and IGF-1 production or treated with these hormones showed a positive association with the risk to develop several types of cancer. In conclusion, athletes should be made aware that long-term treatment with doping agents might increase the risk of developing cancer, especially if associated with other licit or illicit drugs and/or high-protein diet.
Collapse
|
23
|
Zhu A, Galle P, Llovet J, Finn R, Kang YK, Yen C, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Meyer T, Widau R, Schelman W, Wang C, Hsu Y, Kudo M. Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.079] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Kudo M, Galle P, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomasek J, Borg C, Zagonel V, Morimoto M, Pracht M, Finn R, Llovet J, Homma G, Jen MH, Shinozaki K, Yoshikawa R, Zhu A. Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.083] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
25
|
Meyer T, Finn R, Kudo M, Kang Y, Yen C, Galle P, Llovet J, Assenat E, Brandi G, Motomura K, Okusaka T, Hubner R, Karwal M, Baron A, Ikeda M, Liang K, Wang C, Widau R, Schelman W, Zhu A. Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Bisello S, Palloni A, Buwenge M, Autorino R, Cellini F, Tagliaferri L, Gabriella M, Deodato F, Picardi V, Mignona S, Cilla S, Perri V, Tringali A, Galuppi A, Brandi G, Morganti A, Cammelli S, Valentini V, Mattiucci G. EP-1422 Unresectable biliary cancer: results of a pooled analysis of combined CHEMORADIOTHERAPY. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31842-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Tavolari S, Deserti M, Vasuri F, Curti S, Palloni A, Pinna AD, Cescon M, Frega G, De Lorenzo S, Barbera MA, Garajova I, Ricciardiello L, Malvi D, D'Errico-Grigioni A, Pantaleo MA, Brandi G. Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments. Eur J Cancer 2018; 106:160-170. [PMID: 30528800 DOI: 10.1016/j.ejca.2018.11.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 10/26/2018] [Accepted: 11/01/2018] [Indexed: 12/27/2022]
Abstract
Human equilibrative nucleoside transporter 1 (hENT-1) is a membrane nucleoside transporter mediating the intracellular uptake of nucleosides and their analogues. hENT-1 was recently reported to have a predictive role in intrahepatic cholangiocarcinoma (iCC) patients receiving adjuvant gemcitabine-based chemotherapy, but its biological and clinical significance in iCC remains unsettled. This study investigated the role of hENT-1 in regulating tumour growth and predicting the survival of 40 resected iCC patients not receiving adjuvant treatments. hENT-1 expression was found to be significantly higher in iCC than in the matched non-tumoural liver. Patients harbouring hENT-1 localised on the tumour cell membrane had a worse overall survival than membrane hENT-1-negative patients (median 21.2 months vs 30.3 months, p = 0.031), with an adjusted hazard ratio of 2.8 (95% confidence interval 1.01-7.76). Moreover, membrane hENT-1-positive patients had a higher percentage of Ki67-positive cells in tumour tissue than membrane hENT-1-negative patients (median 23% vs 5%, p < 0.0001). Functional analyses in iCC cell lines revealed that hENT-1 silencing inhibited cell proliferation and induced apoptosis in HUH-28 cells expressing hENT-1 on the cell membrane, but not in SNU-1079 cells expressing the transporter only in the cytoplasm. Overall, these findings suggest that membrane hENT-1 is involved in iCC proliferation and associated with worse survival in resected iCC patients. Further prospective studies on larger cohorts are required to confirm these results and better define the potential prognostic role of membrane hENT-1 in this setting of patients.
Collapse
Affiliation(s)
- S Tavolari
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy; Center for Applied Biomedical Research, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - M Deserti
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy; Center for Applied Biomedical Research, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - F Vasuri
- "F. Addarii" Institute of Oncology and Transplantation Pathology, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - S Curti
- Department of Medical and Surgical Sciences, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - A Palloni
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - A D Pinna
- Division of Surgery and Transplantation, S. Orsola- Malpighi University Hospital, Bologna, Italy
| | - M Cescon
- Division of Surgery and Transplantation, S. Orsola- Malpighi University Hospital, Bologna, Italy
| | - G Frega
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - S De Lorenzo
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - M A Barbera
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - I Garajova
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - L Ricciardiello
- Department of Medical and Surgical Sciences, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - D Malvi
- "F. Addarii" Institute of Oncology and Transplantation Pathology, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - A D'Errico-Grigioni
- "F. Addarii" Institute of Oncology and Transplantation Pathology, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - M A Pantaleo
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy
| | - G Brandi
- Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy; Center for Applied Biomedical Research, S. Orsola-Malpighi University Hospital, Bologna, Italy.
| |
Collapse
|
28
|
Kang YK, Kudo M, Lim HY, Hsu CH, Vogel A, Brandi G, Cheng R, Carton I, Abada P, Hsu Y, Zhu A, Yen CJ. Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Murgioni S, Rousseau BC, Scartozzi M, Dahan L, Boussaha T, Crusz S, Meurisse A, Lievre A, Vernerey D. Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Dadduzio V, Rizzato M, Ramondo G, Vivaldi C, Milella M, Brandi G, Cereda S, Murgioni S, Cardellino G, Filippi R, Santini D, Pasquini G, Intini R, Vaccaro V, Palloni A, Reni M, Musettini G, Gringeri E, Aliberti C, Zagonel V. Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): Outcomes and safety from a multicenter Italian experience. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Santini D, Brandi G, Aprile G, Russano M, Cereda S, Leone F, Lonardi S, Fornaro L, Scartozzi M, Silvestris N, Barni S, Pantano F, Vincenzi B, Palloni A, Frega G, Casagrande M, Ferrari L, Dadduzio V, Intini R, Filippi R, Vasile E, Vivaldi C, Faloppi L, Brunetti O, Reni M, Aglietta M, Tonini G. Bone metastases in biliary cancers: A multicenter retrospective survey. J Bone Oncol 2018; 12:33-37. [PMID: 30042924 PMCID: PMC6054714 DOI: 10.1016/j.jbo.2017.11.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2017] [Revised: 11/18/2017] [Accepted: 11/24/2017] [Indexed: 10/24/2022] Open
Abstract
•Natural history of biliary cancers metastatic to bone•The role of skeletal events in patients with biliary cancer•Biliary cancer and bone metastases: role of bisphosphonates.
Collapse
Affiliation(s)
- D Santini
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - G Brandi
- Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - G Aprile
- Department of Oncology, San Bortolo Hospital, ULSS8 Berica–East District, Vicenza, Italy
- Department of Oncology, University and General Hospital, Udine, Italy
| | - M Russano
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - S Cereda
- Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - F Leone
- Department of Oncology, University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy
| | - S Lonardi
- Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - L Fornaro
- Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Italy
| | - M Scartozzi
- Medical Oncology, Hospital & University of Cagliari, Italy
| | - N Silvestris
- Medical Oncology Unit, Cancer Institute ``Giovanni Paolo II'', 70124 Bari, Italy
| | - S Barni
- Medical Oncology Unit, ASST Bergamo Ovest, Piazzale Ospedale 1, 24047 Treviglio, Bergamo, Italy
| | - F Pantano
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - B Vincenzi
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - A Palloni
- Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - G Frega
- Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - M Casagrande
- Department of Oncology, University and General Hospital, Udine, Italy
| | - L Ferrari
- Department of Oncology, University and General Hospital, Udine, Italy
| | - V Dadduzio
- Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - R Intini
- Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - R Filippi
- Department of Oncology, University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy
| | - E Vasile
- Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Italy
| | - C Vivaldi
- Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Italy
| | - L Faloppi
- Medical Oncology, Hospital of Macerata, Macerata, Italy & Medical Oncology, University of Cagliari, Italy
| | - O Brunetti
- Medical Oncology Unit, Cancer Institute ``Giovanni Paolo II'', 70124 Bari, Italy
| | - M Reni
- Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - M Aglietta
- Department of Oncology, University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy
| | - G Tonini
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| |
Collapse
|
32
|
Pileri S, Brandi G, Rivano MT, Govoni E, Martinelli G. Report of a Case of Non-Hodgkin's Lymphoma of Large Multilobated Cell Type with B-Cell Origin. Tumori 2018; 68:543-8. [PMID: 6984803 DOI: 10.1177/030089168206800616] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Large multilobated nuclei lymphoma is a rare entity that is characterized morphologically by large neoplastic elements with prominent nuclear lobations and clinically by a predilection for extranodal sites and a favorable prognosis. According to the data collected to date, the neoplasia is thought to be of T-cell origin. The authors describe the clinical, morphologic and immunohistochemical findings of a case of non-Hodgkin's lymphoma with large multilobated nuclei that showed a definite B-lymphocyte origin.
Collapse
|
33
|
Abstract
A clinico-pathologic study of 20 consecutive patients with leiomyosarcoma of the uterus seen over a 12-year period has been evaluated. Tumor extent at the time of diagnosis seems to be the main prognostic factor: 62.5% of the patients in stage I are alive and well from 1 to 7 years after the diagnosis as compared to 0% of the patients in all the other stages. The age of the patients and the number of mitotic figures also appear to have some prognostic value.
Collapse
|
34
|
Filippi R, Frega G, Vivaldi C, Casadei Gardini A, Aprile G, Silvestris N, Satolli M, Faloppi L, Santini D, Lutrino E, Vasile E, Valgiusti M, Basile D, Brunetti O, Spadi R, Russano M, Scartozzi M, Cagnazzo C, Brandi G, Leone F. Biliary tract carcinoma and chronic viral hepatitis in Italy: the GICO (Gruppo Italiano COlangiocarcinoma) experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Abbati F, Massucci M, Mollica V, Palloni A, Barbera M, Frega G, Ferracin M, Porcellini E, Brandi G, Biasco G, Garajová I. Focus on metastatic right-sided colon cancer: the best overall response to the first-line non-EGFR treatment correlates with better overall survival. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Brandi G, Deserti M, Astolfi A, Indio V, Farioli A, Mattioli S, Palloni A, De Lorenzo S, Garajova I, Vasuri F, Pinna A, Cescon M, Tavolari S. Whole-exome sequencing analysis identifies recurrent mutation rate in BAP1 gene in intrahepatic cholangiocarcinoma patients exposed to asbestos. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
37
|
Massucci M, Francesca A, Veronica M, Palloni A, Frega G, Ferracin M, Porcellini E, Brandi G, Biasco G, Garajová I. Radically resected stage III colorectal cancer: sidedness and prognosis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Marinelli I, Fuccio L, Guido A, Farioli A, Panni V, Ercolani G, Brandi G, Cammelli S, Galuppi A, Macchia G, Frakulli R, MAttiucci G, Cellini F, Buwenge M, Renzulli M, Deodato F, Cilla S, Valentini V, Tombolini V, Golfieri R, Morganti A. PO-0689: clinical target volume in biliary carcinoma: a systematic review of pathological studies. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31126-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Ruggiero C, Bonamassa L, Pelini L, Prioletta I, Cianferotti L, Metozzi A, Benvenuti E, Brandi G, Guazzini A, Santoro GC, Mecocci P, Black D, Brandi ML. Early post-surgical cognitive dysfunction is a risk factor for mortality among hip fracture hospitalized older persons. Osteoporos Int 2017; 28:667-675. [PMID: 27717957 DOI: 10.1007/s00198-016-3784-3] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Accepted: 09/22/2016] [Indexed: 01/29/2023]
Abstract
UNLABELLED This study investigates the relationship between cognitive dysfunction or delirium detected in the early post-surgical phase and the 1-year mortality among 514 hip fracture hospitalized older persons. Patients with early cognitive dysfunction or delirium experienced a 2-fold increased mortality risk. Early post-operative cognitive dysfunction and delirium are negative prognostic factors for mortality. BACKGROUND AND PURPOSE Premorbid cognitive impairment and dementia in older individuals negatively affect functional recovery after hip fracture. Additionally, post-operative delirium is an established risk factor for negative outcomes among hip fracture patients. While the majority of hip fracture patients experience minor post-surgical cognitive dysfunction, the prognostic value of this phenomenon is unknown. Therefore, we investigated the relationship between minor cognitive dysfunction or delirium detected in the early post-surgical phase and the 1-year mortality after index hip fracture. SUBJECTS AND METHODS We enrolled 514 patients with hip fracture (77.4 % women), aged 65 years or older (mean age 83.1 ± 7.3 years), who underwent surgical hip fracture repair. Patients were assessed daily from the second to the fourth post-operative day and at 3, 6, and 12 months thereafter. All participants underwent comprehensive assessment, including detection of delirium by using the confusion assessment method and evaluation of cognitive function by using mini-mental state examination (MMSE; score range 0 to 30, with lower scores indicating poorer performance). In the absence of delirium, post-surgical cognitive dysfunction was defined as having low performance on MMSE. Vital status of 1 year after the index fracture and date of death were gathered from local registries. RESULTS The observed 1-year mortality rate was 14.8 %. Men were more likely to die than women within 1 year of the index fracture (p < 0.01). Compared to participants with better cognitive performance, those with MMSE < 24, as well as those with delirium in the post-operative phase, showed a significantly higher 1-year mortality rate (23.3 versus 17.9 and 8.1 %, respectively). Independent of age and sex, post-operative cognitive dysfunction as well as delirium was both associated with a 2-fold increased mortality risk. CONCLUSIONS The presence of minor cognitive dysfunction in the early post-surgical phase is a negative prognostic factor for mortality among elderly hip fracture patients. The burden of minor cognitive dysfunction is likely superimposed on that of delirium in subgroups of frail patients.
Collapse
Affiliation(s)
- C Ruggiero
- Institute of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Perugia, Italy
| | - L Bonamassa
- Department of Internal Medicine, University of Florence, Largo Palagi 1, 50139, Florence, Italy
| | - L Pelini
- Institute of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Perugia, Italy
| | - I Prioletta
- Institute of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Perugia, Italy
| | - L Cianferotti
- Department of Internal Medicine, University of Florence, Largo Palagi 1, 50139, Florence, Italy
| | - A Metozzi
- Department of Internal Medicine, University of Florence, Largo Palagi 1, 50139, Florence, Italy
| | - E Benvenuti
- Local Health Authority of Florence, Florence, Italy
| | - G Brandi
- Local Health Authority of Florence, Florence, Italy
| | - A Guazzini
- Department of Science of Education and Psychology, University of Florence, Florence, Italy
| | - G C Santoro
- Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, NY, USA
| | - P Mecocci
- Institute of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Perugia, Italy
| | - D Black
- University of California, San Francisco, CA, USA
| | - M L Brandi
- Department of Internal Medicine, University of Florence, Largo Palagi 1, 50139, Florence, Italy.
| |
Collapse
|
40
|
Gatto L, Nannini M, Saponara M, Di Scioscio V, Beltramo G, Frezza GP, Ercolani G, Pinna AD, Astolfi A, Urbini M, Brandi G, Biasco G, Pantaleo MA. Radiotherapy in the management of gist: state of the art and new potential scenarios. Clin Sarcoma Res 2017; 7:1. [PMID: 28078078 PMCID: PMC5223331 DOI: 10.1186/s13569-016-0065-z] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Accepted: 12/16/2016] [Indexed: 12/14/2022] Open
Abstract
Background Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. The main treatment for localized gastrointestinal stromal tumors is surgical resection. Unresectable or advanced GIST are poorly responsive to conventional cytotoxic chemotherapy but the introduction of tyrosine kinase inhibitors (TKIs) marked a revolutionary step in the treatment of these patients, radically improving prognosis and clinical benefit. Historically GIST has been considered radiation-resistant, and the role of radiotherapy in the management of patients with GIST is currently restricted to symptomatic palliation in current treatment guidelines. Case presentation Here we report two patients affected by metastatic GIST, treated with radiotherapy and radiosurgery in combination with TKIs, achieving an unexpected objective response in the first case and a significant clinical benefit associated with a local tumor control of several months in the second case. Conclusions These and other successful experiences that are progressively accumulating, open up new scenarios of use of radiation therapy in various settings of treatment. GIST is not universally radioresistant and radiotherapy, especially if combined with molecularly targeted therapy, can improve the outcomes for patients diagnosed with GIST.
Collapse
Affiliation(s)
- L Gatto
- Department of Specialized, Experimental, and Diagnostic Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - M Nannini
- Department of Specialized, Experimental, and Diagnostic Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - M Saponara
- Department of Specialized, Experimental, and Diagnostic Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - V Di Scioscio
- Department of Radiology, S. Orsola Malpighi Hospital, Bologna University, Bologna, Italy
| | - G Beltramo
- Centro Diagnostico Italiano, Reparto Cyberknife, Milan, Italy
| | - G P Frezza
- Radiation Oncology Unit, Bellaria Hospital, Bologna, Italy
| | - G Ercolani
- Department of General and Emergency Surgery and Organ Transplantation, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - A D Pinna
- Department of General and Emergency Surgery and Organ Transplantation, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - A Astolfi
- Interdepartmental Centre of Cancer Research "G. Prodi", University of Bologna, Bologna, Italy
| | - M Urbini
- Interdepartmental Centre of Cancer Research "G. Prodi", University of Bologna, Bologna, Italy
| | - G Brandi
- Department of Specialized, Experimental, and Diagnostic Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy ; Interdepartmental Centre of Cancer Research "G. Prodi", University of Bologna, Bologna, Italy
| | - G Biasco
- Department of Specialized, Experimental, and Diagnostic Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy ; Interdepartmental Centre of Cancer Research "G. Prodi", University of Bologna, Bologna, Italy
| | - M A Pantaleo
- Department of Specialized, Experimental, and Diagnostic Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy ; Interdepartmental Centre of Cancer Research "G. Prodi", University of Bologna, Bologna, Italy
| |
Collapse
|
41
|
Brandi G, Casabianca A, Schiavano G, Rossi L, Fraternale A, Albano A, Magnani M. Efficacy and Toxicity of Long-Term Administration of 2′,3′-dideoxycytidine in the LP-BM5 Murine-Induced Immunodeficiency Model. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029500600304] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The LP-BM5 murine retrovirus-induced immunodeficiency model was used to evaluate the efficacy and toxicity of long-term 2′,3′-dideoxycytidine (DDC) therapy. A mean plasma drug concentration of 0.2 + 0.02 μm of DDC for 3 months was found to reduce splenomegaly, lymphoadenopathy and hypergammaglobulinemia in infected mice. However, DDC also reduced spleen weight in control mice and spleen haemopoiesis in both infected and uninfected animals. In the bone marrow the most prominent feature of DDC treatment was a marked reduction of megakariocytes, while in the liver an hepatocellular vacuolation was evident in uninfected animals. DDC reduced, but did not prevent, LP-BM5 integration in lymph node DNA and Pr 60gag expression in spleen lymphocytes and bone marrow cells. Furthermore, DDC reduced the mitochondrial DNA content and restored the mitogen proliferation of T cells but not that of B cells in infected mice. Thus, DDC appears to be of some, but limited, efficacy in murine AIDS, with a toxicity profile involving more cell types than previously thought.
Collapse
Affiliation(s)
- G. Brandi
- Istituto di Chimica Biologica ′G. Fornaini’ and Hygiene, Università degli Studi, Via Saffi, 2, 61029 Urbino, Italy
| | - A. Casabianca
- Istituto di Chimica Biologica ′G. Fornaini’ and Hygiene, Università degli Studi, Via Saffi, 2, 61029 Urbino, Italy
| | - G.F. Schiavano
- Istituto di Chimica Biologica ′G. Fornaini’ and Hygiene, Università degli Studi, Via Saffi, 2, 61029 Urbino, Italy
| | - L. Rossi
- Istituto di Chimica Biologica ′G. Fornaini’ and Hygiene, Università degli Studi, Via Saffi, 2, 61029 Urbino, Italy
| | - A. Fraternale
- Istituto di Chimica Biologica ′G. Fornaini’ and Hygiene, Università degli Studi, Via Saffi, 2, 61029 Urbino, Italy
| | - A. Albano
- Istituto di Chimica Biologica ′G. Fornaini’ and Hygiene, Università degli Studi, Via Saffi, 2, 61029 Urbino, Italy
| | - M. Magnani
- Istituto di Chimica Biologica ′G. Fornaini’ and Hygiene, Università degli Studi, Via Saffi, 2, 61029 Urbino, Italy
| |
Collapse
|
42
|
Brandi G, Puddu P, Casabianca A, Cianfriglia M, Magnani M. The Inhibitory Effect of ddC on Human Immunodeficiency Virus Replication Diminishes in Cells that are Chronically Exposed to the Drug. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029700800205] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
One possible explanation for the failure of human immunodeficiency virus type 1 (HIV-1) antiretroviral inhibitors to block the clinical progression of the infection may be a failure to maintain adequate drug levels at the site of viral replication. We have previously found that exposure of human monoblastoid cells (U937) for several months to a therapeutically relevant concentration (0.1 μM) of 2′,3′-dideoxycytidine (zalcitabine, ddC) allowed the isolation of a drug-resistant cell line characterized by a normal drug transport but a reduced ability to accumulate 2′,3′-dideoxycytidine 5′-triphosphate (the active antiretroviral form of the drug). In this paper we show that the drug-resistant cells were indistinguishable from normal cells in terms of surface CD4 receptors. The susceptibility of parental and ddC-resistant U937 cells to infection by HIV-1 was similar, as measured by proviral DNA formation. However, HIV-1 p24 production and the number of infectious virus particles produced were significantly lower in the drug-resistant compared to control cells. Addition of 0.1 μM ddC inhibited viral production by up to 92% in the control cells but had no effect on ddC-resistant cells. Thus, human cells exposed to therapeutically relevant ddC concentrations for several months show a reduced ddC anabolism and allow ddC-sensitive HIV-1 to replicate in the presence of inhibitory ddC concentrations.
Collapse
Affiliation(s)
- G Brandi
- Institute of Hygiene and ‘G. Fornaini’, University of Urbino, 61029 Urbino, Italy
| | - P Puddu
- Laboratory of Immunology, Istituto Superiore di Sanità, 00161 Rome, Italy
| | - A Casabianca
- Biological Chemistry ‘G. Fornaini’, University of Urbino, 61029 Urbino, Italy
| | - M Cianfriglia
- Laboratory of Immunology, Istituto Superiore di Sanità, 00161 Rome, Italy
| | - M Magnani
- Laboratory of Immunology, Istituto Superiore di Sanità, 00161 Rome, Italy
| |
Collapse
|
43
|
Magnani M, Casabianca A, Rossi L, Fraternale A, Brandi G, Silvotti L, Piedimonte G. Inhibition of HIV-1 and LP-BM5 Replication in Macrophages by Dideoxycytidine and Dideoxycytidine 5′-Triphosphate. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029500600505] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The antiviral agent 2′,3′-dideoxycytidine (ddC) has been shown to be active against HIV-1 infectivity. However, conflicting results have been reported concerning its efficacy in macrophages. Because macrophages possess low levels of the kinase(s) responsible for ddC phosphorylation, we investigated the ability of ddC and 2′,3′-dideoxycytidine 5′-trisphosphate (ddCTP) to suppress HIV-1 and LP-BM5 replication in these cells. Retrovirus replication was only partially inhibited in the two systems investigated by a high (1 μM) ddC concentration. The direct administration of ddCTP, using autologous red blood cells as a delivery system, was found to inhibit HIV-1 and LP-BM5 replication by more than 90% in macrophages without affecting major cell functions. These data, together with those already reported for FIV [Magnani et al. (1994) AIDS Res Hum Retroviruses 10: 1179-1186], suggest that the anabolic phosphorylation of ddC is an important determinant of its anti-HIV activity and that pharmacological interventions that modulate ddC metabolism may be useful for improving its antiretroviral activity in macrophages.
Collapse
Affiliation(s)
- M. Magnani
- Istituto di Chimica Biologica ‘G. Fornaini’, University of Urbino, Via Saffi, 2-61029 Urbino, Via S Chlara, 61023 Urbino, Italy
| | - A. Casabianca
- Istituto di Chimica Biologica ‘G. Fornaini’, University of Urbino, Via Saffi, 2-61029 Urbino, Via S Chlara, 61023 Urbino, Italy
| | - L. Rossi
- Istituto di Chimica Biologica ‘G. Fornaini’, University of Urbino, Via Saffi, 2-61029 Urbino, Via S Chlara, 61023 Urbino, Italy
| | - A. Fraternale
- Istituto di Chimica Biologica ‘G. Fornaini’, University of Urbino, Via Saffi, 2-61029 Urbino, Via S Chlara, 61023 Urbino, Italy
| | | | - L. Silvotti
- Anatomia Patologica Veterinaria, University of Parma, Via Del Taglio, 43100 Parma, Italy
| | - G. Piedimonte
- Anatomia Patologica Veterinaria, University of Parma, Via Del Taglio, 43100 Parma, Italy
| |
Collapse
|
44
|
Brandi G, Cereda S, Pantano F, Russano M, Lonardi S, Leone F, Reni M, Marsico V, Filippi R, Delcuratolo S, Fornaro L, Vasile E, Vivaldi C, Aprile G, Pisconti S, Luca F, Aieta M, Tonini G, Santini D. Natural history of skeletal disease in primary biliary cancers. National survey on behalf of GICO group (Gruppo Italiano Colangiocarcinoma – Onlus). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Garajová I, Brandi G, Biasco G, Deserti M, Tavolari S, Palloni A, Verlicchi L, Le Large T, Di Piazza D, Giovannetti E. MiR-21 expression as prognostic biomarker in extrahepatic but not intrahepatic radically resected cholangiocarcinomas. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
46
|
Fornaro L, Cereda S, Leone F, Aprile G, Lonardi S, Silvestris N, Santini D, Milella M, Palloni A, Barbera A, Ferrari L, Filippi R, Bergamo F, Vivaldi C, Caparello C, Musettini G, Pasquini G, Falcone A, Reni M, Brandi G, Vasile E. Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (pts) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Garajová I, Brandi G, Biasco G, Deserti M, Tavolari S, Palloni A, Verlicchi L, Le Large T, Giovannetti E. 219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30106-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
48
|
Chau I, Park J, Ryoo B, Yen C, Poon R, Pastorelli D, Blanc J, Kudo M, Pfiffer T, Hatano E, Chung H, Kubackova K, Phelip J, Brandi G, Ohkawa S, Li C, Okusaka T, Yang L, Abada P, Zhu A. 2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31253-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
49
|
Fornaro L, Vivaldi C, Brandi G, Cereda S, Aprile G, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Caparello C, Musettini G, Pasquini G, Vasile E. P-147 Outcome of second-line chemotherapy (CT2) after first-line CT (CT1) with platinum plus gemcitabine in advanced biliary tract cancer (aBTC): is it worthwhile? Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
50
|
Marsico V, Vasile E, Brandi G, Leone F, Santini D, Aprile G, Cereda S, Silvestris N, Milella M, Bergamo F, Fornaro L, Bolshinsky M, Paladina I, Lonardi S, Aliberti C. P-115 Transarterial Chemo-Embolization (TACE) and Radio-Embolization (TARE) in the combined modality treatment of advanced biliary tract cancer (aBTC): evaluation of feasibility and activity. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|